Streetbeat News

Analyst Ratings

GTHX

The American Society of Clinical Oncology has updated its guidelines for small cell lung cancer to include G1 Therapeutics' COSELA. This recommendation could potentially increase the usage of COSELA, benefiting G1 Therapeutics.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 12:15 pm

LMT

Citigroup analyst Jason Gursky maintains a Buy rating on Lockheed Martin (NYSE:LMT) but has lowered the price target from $555 to $540.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 12:13 pm

CBAY

CymaBay Therapeutics (NASDAQ:CBAY) announced that results from the RESPONSE Phase 3 study of seladelpar in patients with primary biliary cholangitis (PBC) will be presented at The Liver Meeting® of the American Association for the Study of Liver Diseases (AASLD). Seladelpar is a potent, selective, orally active delpar or PPARδ agonist, in development for the treatment of adult patients with PBC. The company looks forward to sharing the results, which is an important step forward in obtaining regulatory review and potentially marketing authorization.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 12:13 pm

FBK

Janney Montgomery Scott analyst Feddie Stickland has upgraded FB Financial (NYSE:FBK) from Neutral to Buy and announced a price target of $35.5.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 12:13 pm

ERIC

JP Morgan analyst Sandeep Deshpande maintains an Overweight rating on Telefonaktiebolaget L M (NASDAQ:ERIC) but lowers the price target from $8.3 to $7.78.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 12:08 pm

HUN

B of A Securities analyst Steve Byrne has upgraded Huntsman (NYSE:HUN) from Underperform to Buy and set a price target of $27.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 12:08 pm

CMG

CTV

ESTC

MA

NKTX

NVDA

SBSW

TMO

V

WEN

Top Wall Street analysts have updated their outlooks on several stocks. Raymond James cut Chipotle's price target from $2,300 to $2,100 and Wedbush slashed Wendy's price target from $26.5 to $24. Keybanc raised Visa's price target from $265 to $275 and increased Mastercard's price target from $435 to $440. Jefferies increased Elastic's price target from $75 to $100. RBC Capital cut Sibanye Stillwater's price target from $9 to $6.5. Needham cut Innovid's price target from $3 to $1.5. Raymond James slashed Thermo Fisher Scientific's price target from $630 to $580. HC Wainwright & Co. lowered Nkarta's price target from $16 to $10. Citigroup slashed NVIDIA's price target from $630 to $575.

Portfolio Pulse from Lisa Levin

October 18, 2023 | 12:04 pm

LYB

B of A Securities analyst Steve Byrne has upgraded LyondellBasell Industries (NYSE:LYB) from Underperform to Neutral and raised the price target from $99 to $107.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 12:02 pm

WULF

Over the last quarter, TeraWulf (NASDAQ:WULF) has received mostly bullish ratings from analysts, with a total of 9 bullish ratings and no bearish or indifferent ratings. The company has an average 12-month price target of $3.89, representing a 2.75% decrease from the previous average price target of $4.00.

Portfolio Pulse from Benzinga Insights

October 18, 2023 | 12:01 pm

LAC

Over the past 3 months, 4 analysts have published their opinion on Lithium Americas (NYSE:LAC) stock. The average price target is $17.75, implying an upside from the current price of $8.81. However, this average has decreased by 38.79% from the previous average price target of $29.00.

Portfolio Pulse from Benzinga Insights

October 18, 2023 | 12:01 pm